US Fertility has announced a groundbreaking partnership with Alife Health to integrate AI-powered embryo imaging and reporting across its nationwide network of fertility practices. This collaboration will provide patients with personalized IVF laboratory summary reports, including embryo images, laboratory-generated grading, clinical significance, and next steps.
Richard Jennings, CEO of US Fertility, highlighted the transformative nature of this partnership, emphasizing that AI technology will set a new industry standard in delivering IVF services while optimizing the patient experience. Alife’s Embryo Assist tool aims to streamline the manual process of embryo grading by integrating seamlessly with microscopes and EMRs, allowing embryologists to efficiently capture and organize data.
Dr. Kate Devine, Medical Director of US Fertility, praised the integration of AI technology for its positive impact on operational efficiencies and patient experience. Melissa Teran, CEO of Alife, described the partnership as a gamechanger for the fertility industry, highlighting US Fertility’s endorsement of their technological approach to IVF.
This collaboration will benefit US Fertility’s network of over 100 clinics and 32 IVF laboratories across the United States, ultimately improving patient care for tens of thousands of individuals annually. The partnership reflects a significant step towards enhancing the future of fertility treatments through the innovative use of AI technology in the field.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
